EDMONTON, Alberta, April 17 /PRNewswire-FirstCall/ -- Medical Services International Inc. (OTC:MSITF) is pleased to announce that its combined rapid test kit for HIV and Tuberculosis (TB) is now fully tested internally and is ready for independent testing in the market. The independent testing will start by the end of April, 2006. This dual flow test kit detects both HIV and TB simultaneously. It is a well known statistic that Thirty-five (35%) of the individuals that test positive for HIV have TB. TB is a highly contagious airborne infectious disease that will kill over two million people this year. This is more than all of the other infectious diseases combined. If detected early, TB is a relatively easy disease to cure. The combined VScan HIV/TB test kit is the ONLY kit that can detect both HIV/TB at the same time. It is an ideal kit in remote areas where TB cannot be tested for because of the lack of trained medical personnel and no medical facilities. It is the first of its kind in the marketplace and in areas where the incidence of TB is high it will be an invaluable tool for the early detection of HIV/TB. This combined test kit is expected to generate significant revenue for the Company. About VScan The VScan rapid test kit is a single use, easy to use test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis and Prostate Cancer. The kits cannot be used in Canada. Medical Services International Inc trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/ . NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies, DATASOURCE: Medical Services International Inc. CONTACT: Robert Talbot of Medical Services International, +1-780-430-6363 Web site: http://www.minerva-biotech.com/ http://www.medicalservicesintl.com/

Copyright